[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sunnybrook Health Sciences Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":656},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,116,0,25,[9,51,77,102,126,154,183,210,247,270,291,315,347,377,403,427,451,471,493,519,538,564,591,610,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100388301","enhancing-outcomes-in-cognitive-impairment-through-use-of-home-sleep-apnea-testing-100388301",false,"NCT04335994","ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing","ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing: A Randomized Controlled Trial (ENCHANT Study)","ENCHANT","Inclusion Criteria:\n\n* Evidence of cognitive impairment by any one of: (i) Montreal Cognitive Assessment (MoCA) score of 13-28, or (ii) Mini Mental State Examination (MMSE) score of 18-30, or (iii) Toronto Cognitive Assessment (TorCA) score ≤281.\n* A diagnosis of: (i) Single-domain amnestic or multiple cognitive domain (with one feature being amnestic) Mild Cognitive Impairment due to Alzheimer's disease (AD); or (ii) Probable AD dementia; or (iii) Possible AD dementia due to limited concomitant cerebrovascular disease; or (iv) Probable Vascular dementia or Vascular Mild Cognitive Impairment, as per the 2011 American Heart Association Scientific Statement; or (v) Patients with a suspected neurodegenerative condition known to be associated with non-OSA sleep disorders (e.g. Parkinson's disease-related dementia and dementia with Lewy Bodies); and\u002For (vi) Mixed disease\n* Have the competency to provide informed consent, or the availability of a substitute decision maker\u002Fcaregiver who can provide consent (if needed).\n* The availability of a caregiver to assist in the completion of HSAT or iPSG, if needed.\n\nExclusion Criteria:\n\n* Prior diagnosis of OSA within the last 2 years\n* Patients already using CPAP or a dental appliance for previously diagnosed OSA.\n* A known contraindication for the use of the HSAT that will be used in this study: (a) Moderate to severe pulmonary disease or congestive heart failure that could compromise the validity of the HSAT results (in users of the ApneaLink); (b) Permanent pacemaker or history of sustained non-sinus cardiac arrhythmia (in users of the WatchPAT).\n* Any medical device that would interfere with the placement of the HSAT\n* Significant physical impairment or language barrier that would restrict the ability to use the HSAT or complete the study assessments.","ALL",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Obstructive sleep apnea (OSA), which causes abnormal pauses in breathing during sleep, is common in patients with vascular cognitive impairment (VCI) and Alzheimer's disease (AD), and exacerbates the cognitive deficits seen in these conditions. OSA is typically treated with continuous positive airway pressure (CPAP), which has been shown to improve cognition in VCI and slow cognitive decline in AD. Despite the need to identify OSA in patients with VCI\u002FAD, these patients often do not undergo testing for OSA. One major barrier is that in-laboratory polysomnography (iPSG), the current standard for diagnosing OSA, is inconvenient for patients with VCI\u002FAD who may be reliant on others for care or require familiar sleep environments. A convenient and cheaper alternative to iPSG is home sleep apnea testing (HSAT), which has been validated against iPSG to diagnose OSA and has proven feasible for use in VCI\u002FAD. Our primary objective is to determine whether the use of HSAT is superior to iPSG in terms of the proportion of patients who complete sleep testing by 6 months post-randomization. We will also investigate cost-effectiveness, patient satisfaction, proportion of patients treated with CPAP, changes in cognition, mood, sleep-related and functional outcomes between HSAT and iPSG at 6 months.",[27,28,29,30,31,32,33],"Obstructive Sleep Apnea","Alzheimer Disease","Vascular Dementia","Mild Cognitive Impairment","Parkinsons Disease With Dementia","Dementia With Lewy Bodies","Mixed Dementia",[27,35,36,37],"Cognitive Impairment","Home Sleep Apnea Test","Screening","RECRUITING","2026-08-19",{"date":41,"type":42},"2026-08-20","ACTUAL",{"date":44,"type":42},"2019-09-23",{"date":46,"type":21},"2027-06",{"name":48,"class":49},"Sunnybrook Health Sciences Centre","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100651776","phase-2-hepatic-arterial-infusion-chemotherapy-in-patients-with-inoperable-colorectal-cancer-liver-metastasis-100651776","NCT07764497","Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis","A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic Chemotherapy in Patients With Inoperable Hepatic Metastasis From Colorectal Cancer","HAIP-6192","Inclusion Criteria:\n\n1. History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Patients with resectable or ablatable lung metastasis are eligible.\n2. Physically able to tolerate major partial hepatectomy.\n3. The primary tumor may be in place at the time of registration if not obstructing the intestinal lumen or significantly bleeding. If present, the primary tumor will be resected at the time of pump placement.\n4. Chest, Abdominal and Pelvic CT scan with CT angiogram within 6 weeks prior to registration. (MRI angiogram with contrast of the abdomen may be substituted for CT of the abdomen).\n5. The patient must have inoperable liver metastases as agreed upon by any two hepatobiliary surgeons and the assigned radiologist. In the event that two hepatobiliary surgeons cannot agree, a third surgeon will be consulted. Continued discrepancy will result in the patient's case being presented at weekly hepatobiliary conference for consensus opinion. Inoperable metastases are defined as: requiring a resection that leaves less than 2 hepatic segments (not including the caudate lobe) behind with adequate arterial\u002Fportal inflow, venous outflow and biliary drainage. \\* A patient is considered resectable if the procedure includes a minor wedge or thermo-ablation encompassing 10% or less of the volume of the remaining 2 segments.\n6. Patient's liver metastases must comprise \\\u003C70% of the liver parenchyma.\n7. Female patients of child-bearing age must undergo a pregnancy test and have a negative result.\n8. A patient must have had prior chemotherapy.\n9. ECOG PS \\\u003C 2.\n10. Within 14 days of registration: o WBC \\>3X10E9\u002FL; ANC ≥ 1.5X10E9\u002FL; Platelet count \\>100X10E9\u002FL; INR \\\u003C 1.5; HGB ≥ 90 g\u002FL; Estimated creatinine clearance ≥30 ml\u002Fmin (using Cockcroft and Gault formula); Total serum bilirubin \\\u003C25.6 umol\u002FL.\n11. Age ≥ 18 years.\n12. Signed informed consent.\n13. Subject's willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n14. Patients with limited\u002Fresponding lung metastases on Physician's discretion.\n\nExclusion Criteria:\n\n1. Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration).\n2. Patient may not have received prior treatment with FUDR.\n3. Active infection, ascites, hepatic encephalopathy.\n4. Active concurrent malignancies, except a patient's potentially resectable colorectal primary.\n5. Extrahepatic metastases except for resectable or ablatable lung metastasis.\n6. Patient must not have obstruction of GI or GU tract.\n7. Female patients who are pregnant or lactating.\n8. Patients may not be receiving any other investigational agents.\n9. Patients with history of primary CNS tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded (history of stroke or transient ischemic attack within 6 months prior to Day 1).\n10. Serious or non-healing active wound, ulcer, or bone fracture.\n11. Chronic daily treatment with aspirin (\\> 325 mg\u002Fd) or nonsteroidal anti- inflammatory medications known to inhibit the platelet function.\n12. Presence of bleeding diathesis or coagulopathy.\n13. History of serious systemic disease, including myocardial infarction within the last 6 months, uncontrolled hypertension (blood pressure of \\> 150\u002F100 mmHg on medication), unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e. atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or peripheral vascular disease (Grade II or greater).","18 Years",{"count":20,"type":21},[62],"PHASE2","The goal of this clinical trial is to assess how many patients with initially inoperable colorectal liver metastasis are able to have a liver surgery after treatment with hepatic artery infusion chemotherapy and standard of care systemic chemotherapy.",[65,66,67,68],"Colorectal Adenocarcinoma Metastatic in the Liver","Liver Metastasis Colon Cancer","Liver Metastases From Colorectal Cancer","Liver Metastases of Colorectal Cancer","2026-08-11",{"date":71,"type":42},"2026-08-14",{"date":73,"type":42},"2014-07",{"date":75,"type":21},"2036-12",{"name":48,"class":49},{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":50},"100607637","phase-3-eary-infusion-of-eptinezumab-for-treatment-of-acute-post-traumatic-headaches-elite-act-100607637","NCT07191145","Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)","EarLy Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT): a Parallel Group, Randomized, Double Blind, Placebo Controlled Trial","Inclusion Criteria:\n\n* Meet diagnostic criteria for acute post-traumatic headache as per ICHD-3 criteria\n* Meet migraine screening questionnaire criteria (MSQ score ≥ 4) during at least one of the weekly screening calls\n* Within 8 weeks after onset of PTH\n\n  \\* Imaging is not required for inclusion\n* Negative human chorionic gonadotropin test before treatment, for female participants of childbearing potential who are not practicing medically appropriate methods of birth control (e.g., hormonal contraceptives, implants, injectables, intrauterine devices, intrauterine systems, etc.)\n\nExclusion Criteria:\n\n* Diagnosis of moderate to severe TBI\n* History of mTBI within the past 5 years\n* Pre-existing chronic migraine and its subtypes, tension-type headache, trigeminal autonomic cephalalgias, cranial neuralgias, daily headache, diagnosis of another secondary headache disorder per ICHD-3 (except medication overuse headache)\n* Concurrent use of CGRP-related treatment or botulinum toxin within the last three month for migraine\n* Substance \u002F opioids use disorder\n* Confounding chronic pain disorder \u002F clinically significant pains\n* Concurrent major injuries (long bone, rib, and spinal fractures) or surgical intervention while in hospital on initial trauma\n* On-going litigation for current trauma\n* Pregnancy\u002Fbreast-feeding\n* Uncontrolled psychiatric conditions (depression, PTSD, anxiety, functional neurological disorder)\n* Use of opioids\u002Fbarbiturates for headaches (\\> 4 days\u002Fmonth)\n* Hereditary fructose intolerance","65 Years",{"count":86,"type":21},80,[88],"PHASE3","Most individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \\> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.",[91],"Post Traumatic Headache",[93],"Migraine","NOT_YET_RECRUITING",{"date":96,"type":42},"2026-08-13",{"date":98,"type":21},"2026-09-30",{"date":100,"type":21},"2027-12-30",{"name":48,"class":49},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":50},"100576161","phase-3-intravenous-ketamine-and-immersive-virtual-reality-to-treat-depression-100576161","NCT06781697","InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression","InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (TREASURE Trial): a Pilot, Randomized Controlled Trial","TREASURE","Inclusion Criteria:\n\n* Age ≥ 18, able to provide informed consent\n* Patient diagnosed with treatment-resistant depression\n* Outpatient recommended and approved by psychiatrist for ketamine treatment\n* Patients who are on IV ketamine and requiring at least 4 treatments of IV ketamine per course (prescribed by their physiatrist)\n* Cognitively alert, oriented, and able to watch immersive content and respond to questions\n* Negative human chorionic gonadotropin test before treatment, for female participants of childbearing potential who are not practicing medically appropriate methods of birth control (e.g., hormonal contraceptives, implants, injectables, intrauterine devices, intrauterine systems, etc.)\n\nExclusion Criteria:\n\n* History of psychosis\u002Fcomorbid psychiatric disorders\u002Fpsychotic depression\u002Fdissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist\n* Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment\n* History of substance misuse and\u002For dependence, including chronic alcohol abuse\n* Previous ketamine use\n* Acute dementia\u002Fdelirium\n* Acute risk of suicide at baseline, as determined by the study psychiatrist\n* Pregnancy\u002Fbreastfeeding\n* Previous sensitivity to ketamine or related compounds\n* Unstable medical condition which may require anesthesia consult\n* History of elevated intracranial pressure or cerebrovascular accident\n* Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction)\n* Significant motion sickness (i.e. occur during exposure to physical\u002Fvisual and virtual motion, cybersickness, etc.) self-identified by patient\n* Inability to communicate with the study team",{"count":111,"type":21},31,[88],"Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people. There is therefore a need for new treatments which work quickly and effectively.\n\nOne such medication is called ketamine. Studies have shown that ketamine can treat symptoms of depression quickly. This quick action sets ketamine apart from many antidepressants that take weeks to show noticeable effects. One way that it may do this is by creating a transient sense or feeling of being separated from reality, such as seeing or hearing things that are not really there. Another way to create these same feelings is with virtual reality (VR), where a person can feel as though they are entering a 3-dimensional virtual computer-generated world by wearing a special headset or goggles with a computer inside.\n\nIn this study, all participants will receive standard ketamine treatments for depression. Half of the participants will also use a VR headset while receiving the ketamine treatments to see if ketamine and VR acting together provide a better treatment for symptoms of depression than ketamine alone.\n\nThis is a small pilot trial. The main purpose of this trial is to learn if it is possible to run a larger clinical trial comparing \"ketamine and VR\" with \"ketamine alone\", for adults with treatment-resistant depression. The researchers will study this by seeing how many participants take part in the study within 1-2 years, and how many complete the study treatments and tests. The researchers will also compare the two study groups to see if \"ketamine and VR\" provide a better treatment for symptoms of depression than \"ketamine alone\".",[115],"Treatment Resistant Depression",[117,118,119,115],"Depression","Ketamine","Virtual Reality",{"date":96,"type":42},{"date":122,"type":42},"2026-05-03",{"date":124,"type":21},"2028-12",{"name":48,"class":49},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":18,"minAge":134,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100548647","phase-4-effect-of-perioperative-duloxetine-administration-on-opioid-consumption-following-total-knee-arthroplasty-relife-100548647","NCT06423716","Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE)","Effect of Perioperative Duloxetine Administration on Opioid Consumption Following Total Knee Arthroplasty","RELIFE","Inclusion Criteria:\n\n1. Age \\>=50\n2. Presence of knee osteoarthritis\n3. Planned for elective unilateral total knee arthroplasty\n4. ASA I - III\n5. Baseline creatinine clearance (CrCl) ≥ 30 mL\u002Fmin within 60 days prior to enrolment, if available. If not available, verbal report from patient of no known renal disease.\n\nExclusion Criteria:\n\n1. Lack of patient consent; unlikely to comply with follow-up\n2. Presence of contraindications to study drug use:\n\n   * Known hypersensitivity to the drug or components of the product\n   * Known liver disease - history of cirrhosis, non-alcoholic steatohepatitis\n   * Uncontrolled narrow - angle glaucoma\n   * Severe renal impairment (CrCl\\\u003C30mL\u002Fmin)\n   * Concurrent use of thioridazine\n   * Concurrent use of potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin)\n   * Concurrent use of antidepressants (e.g. MAOI, SSRI, SNRI, TCA, St. John's Wort, buspirone)\n   * Concurrent use of triptan or lithium\n3. Chronic and high dose opioid use (\\>30mg oral morphine equivalent per day)\n4. Substance use disorder (cannabis and related products, alcohol use disorder, opioid used disorder, illicit drugs)\n5. Uncontrolled hypertension (systolic BP \\> 180mmHg)\n6. Untreated psychiatric illness (e.g. depression, suicidal ideation, bipolar disorder)\n7. Involved in worker's compensation case\u002Flaw suit (verbally declared by patient)","50 Years",{"count":136,"type":21},150,[138],"PHASE4","Knee replacement surgery for osteoarthritis is a commonly performed procedure in Canada with 75,000 of these surgeries performed each year. Success rate for knee replacement surgery is high but more than 20% of patients are still dissatisfied mainly due to reports of ongoing pain. Pain control following knee surgery is important in order to allow patients to engage in recovery and rehabilitation. The current standard of pain management after surgery centers around the use of opioids which is a concerning practice as highlighted by the opioid epidemic. Duloxetine is an antidepressant that has pain relieving properties and it has been studied in patients undergoing knee replacement surgery. Studies to date have not been designed optimally to demonstrate the full effects of opioid dose reduction and the use of duloxetine as a medication following knee replacement surgery. This research study seeks to start duloxetine before surgery, at the recommended therapeutic dose, and for the duration of the early rehabilitation period. If the study is successful, this low-cost medication can improve satisfaction rates and change the standard way the pain management is typically carried out for patients undergoing the knee replacement surgery.",[141],"Knee Osteoarthritis",[143,144,145],"total knee arthroplasty","duloxetine","postoperative pain",{"date":147,"type":42},"2026-08-12",{"date":149,"type":42},"2024-11-01",{"date":151,"type":21},"2027-12-31",{"name":48,"class":49},2,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":161,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":170,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":50},"100619873","comparing-virtual-reality-simulation-to-high-fidelity-simulation-as-an-educational-modality-for-electroconvulsive-therapy-training-a-non-inferiority-study-100619873","NCT07350278","Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therapy Training: A Non-Inferiority Study","ECT-SIM","Inclusion Criteria:\n\n* Is a medical student at the University of Toronto\n* Has not received formal ECT training before\n\nExclusion Criteria:\n\n* Visual or hearing impairment that does not allow the participant to use VR.\n* History of significant motion sickness.",true,{"count":163,"type":21},78,[24],"The goal of this prospective, open-label non-inferiority randomized controlled trial is to investigate if Virtual Reality (VR) based simulation are an effective training tool for novice medical trainees. The main questions it aims to answer are:\n\n* Is the VR-based electroconvulsive therapy (ECT) training program non-inferior to traditional, mannequin-based ECT training programs in fostering ECT skill acquisition?\n* What are the changes in confidence in administering ECT, as well as number of training repetitions completed in the VR and mannequin training groups?\n* What is the ease of use of the VR-based ECT training program? Researchers will compare the VR-based ECT training program to a mannequin-based ECT training program to see if the VR-based ECT training program is comparable to traditional methods at training for ECT.\n\nParticipants will:\n\n* Complete an ECT skills assessment at the beginning and end of the study session.\n* Watch a 30-minute didactic ECT lecture video.\n* Be randomized to either the VR ECT simulation group or the mannequin ECT simulation group and be given 30 minutes to practice ECT administration with their assigned education tool.",[167,168,169],"Education, Medical, Undergraduate","Electroconvulsive Therapy","Virtual Reality Simulation",[171,172,173,174],"virtual reality","mannequin","education","electroconvulsive therapy","2026-08-06",{"date":177,"type":42},"2026-08-10",{"date":179,"type":42},"2026-01-18",{"date":181,"type":21},"2028-03-01",{"name":48,"class":49},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":50},"100651097","erector-spinae-plane-vs-serratus-anterior-plane-catheter-infusions-for-acute-pain-management-in-patients-with-traumatic-rib-fractures-100651097","NCT07756047","Erector Spinae Plane vs Serratus Anterior Plane Catheter Infusions for Acute Pain Management in Patients With Traumatic Rib Fractures","Erector Spinae Plane vs Serratus Anterior Plane Catheter Infusions for Acute Pain Management in Patients With Traumatic Rib Fractures: a Single Centre, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18;\n* Traumatic rib fractures (unilateral or bilateral);\n* Minimum of 3 rib fractures per side;\n* Admitted to hospital for \\\u003C72 hours\n* NRS pain score \\> 4 at rest or with movement for chest pain at the time of eligibility assessment\n\nExclusion Criteria:\n\n* Severe traumatic brain injury (Glasgow Coma Scale \\\u003C 9);\n* Surgery performed\u002Fplanned within 72 hours of catheter infusion start;\n* Uncontrolled coagulopathy;\n* Skin infection or anatomical abnormality (i.e. open fracture) at insertion sites;\n* Allergy to local anesthetic;\n* Chronic high dose opioid use preadmission (Morphine Equivalent Dose \\> 30mg per day);\n* Pregnancy;\n* Acute respiratory failure requiring intubation at enrolment;\n* Inability to comply with Intravenous Patient-Controlled Analgesia use;\n* Contraindications to nerve blocks\n* High likelihood of loss to follow-up",{"count":191,"type":21},66,[24],"Rib fractures happen in about 10-20% of patients with blunt trauma and can be serious, with higher death rates in older adults. These injuries often lead to lung problems like pneumonia, collapsed lung areas (atelectasis), fluid buildup, or even respiratory failure. A major reason for this is pain-patients avoid deep breathing and coughing, which worsens lung function. Good pain control helps prevent these complications.\n\nOpioids are commonly used for pain but can cause problems such as slowed breathing, delirium, nausea, and longer time on a ventilator. Because of this, regional anesthesia (nerve blocks) is increasingly used to control pain while reducing opioid use. Common options include epidurals, paravertebral blocks, and newer techniques like erector spinae plane (ESP) and serratus anterior plane (SAP) blocks. Continuous catheter techniques are especially useful in trauma patients because they can provide ongoing pain relief and have fewer contraindications than epidurals.\n\nThe SAP block is done at the side of the chest and works well for rib fractures in the front and side. It may not work as well for fractures in the back, although trauma may sometimes allow the anesthetic to spread further than expected.\n\nThe ESP block is done near the spine and may cover a broader area, including both front and back of the chest. It is relatively easy to perform at the bedside and is considered safe. Studies suggest it provides pain relief similar to epidurals in some patients.\n\nThere is still limited evidence directly comparing continuous SAP and ESP catheters. Only one study (using single injections) suggests ESP may provide better pain relief. It is unclear whether that difference holds true with continuous infusions, or whether SAP might be preferable because it is easier and quicker to perform.\n\nWe propose a randomized trial comparing continuous ESP and SAP catheters in patients with rib fractures to determine which provides better pain control, reduces opioid use, improves breathing outcomes, and is easier to perform in routine practice.\n\nOur hypotheses are that ESP will provide better pain relief, SAP will be easier and safer to place, and both techniques will reduce opioid use while maintaining good patient comfort and breathing.",[195,196],"Traumatic Rib Fracture(s)","Traumatic Rib Fracture",[198,199,200,201,202],"trauma","rib fracture","regional anesthesia","fascial plane catheter","acute pain","2026-08-04",{"date":177,"type":42},{"date":206,"type":21},"2026-08-01",{"date":208,"type":21},"2028-06-30",{"name":48,"class":49},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":84,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":50},"100621853","ketogenic-diet-and-neuromodulation-in-treatment-resistant-depression-100621853","NCT07376018","Ketogenic Diet and Neuromodulation in Treatment Resistant Depression","Adjunctive Low-carb Ketogenic Diet to Enhance Imaging-guided Neuromodulation in Treatment Resistant Depression","ALIGN","Inclusion Criteria:\n\n* Age 18-65 of any sex, gender identity, ethnicity and socioeconomic status\n* Currently experiencing a major depressive episode as defined by DSM-5-TR criteria and confirmed by a study physician\n* Presenting with at least moderate symptom severity (PHQ ≥ 10)\n* Meeting criteria for treatment-resistant depression (TRD), defined as either: (1) failure to achieve a clinical response to ≥2 adequate antidepressant treatment trials for unipolar depression, OR (2) inability to tolerate ≥2 separate antidepressant treatment trials for unipolar depression, as assessed using the Antidepressant Treatment History Form (ATHF), with a score of ≥3 in the current episode\n* No rTMS treatment received in the current depressive episode (prior rTMS in a previous episode is permitted); no failure to respond to a course of electroconvulsive therapy (ECT) in the current depressive episode\n* Able to provide informed consent\n* Available for the 12-week intervention and willing to follow either a ketogenic or Canadian Food Guide-aligned diet\n* No increase or initiation of any antidepressant or antipsychotic medication in the 4 weeks prior to screening\n\nExclusion Criteria:\n\n* Concomitant major unstable medical illness as determined by a study physician\n* Lifetime diagnosis of bipolar I or bipolar II disorder, or a primary psychotic disorder, as confirmed by a structured psychiatric interview\n* Current psychotic symptoms\n* Diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalised anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary and causing greater impairment than MDD\n* Diagnosis of any personality disorder assessed by a study investigator to be primary and\u002For causing greater impairment than MDD\n* History of epilepsy, stroke, or major neurological conditions, or a history of a primary seizure disorder or a seizure associated with an intracranial lesion\n* Physical or cognitive disability interfering with participation\n* Pregnancy, nursing, or intent to become pregnant during study\n* BMI \\\u003C 20 kg\u002Fm²\n* Suicide attempts in the past 12 months\n* Active suicidal intent as confirmed by study psychiatrist\n* Active eating disorder in the past 12 months\n* Currently following a Ketogenic diet\n* Habitual low-carb diet in the past 6 months\n* GI disorders or food allergies incompatible with dietary protocols\n* Alcohol use \\>3 drinks\u002Fday or \\>14\u002Fweek\n* Use of anticonvulsants (benzodiazepines with a dose of \\\u003C2 lorazepam equivalents will be permitted), GABA agonists, or medications reducing TMS efficacy\n* Contraindications to MRI\n* Unwillingness to perform daily finger-stick testing\n* Inability to access or prepare KD-compliant foods if assigned\n* Unable to provide informed consent on their own",{"count":219,"type":21},60,[24],"The goal of this clinical trial is to learn if combining a ketogenic diet with a personalized, accelerated brain stimulation treatment (iTBS) works better than iTBS with a standard healthy diet to reduce depression symptoms in adults with treatment-resistant depression. The main questions it aims to answer are:\n\n* Does iTBS combined with a ketogenic diet improve depression symptoms more than iTBS combined with a standard healthy diet?\n* Does the ketogenic diet change ketone levels over time?\n* Is it safe, tolerable, and feasible to follow a ketogenic diet during accelerated iTBS treatment?\n\nWe will compare a ketogenic diet to a Canadian Food Guide-aligned diet, both combined with iTBS, measuring depression severity using standard clinician-rated and self-report scales.\n\nParticipants will:\n\n* Follow either a ketogenic diet or a standard healthy diet for 12 weeks, starting with a 3-week lead-in period before iTBS begins\n* Undergo a course of personalized, imaging-guided accelerated iTBS while continuing their assigned diet\n* Complete clinical and cognitive assessments, blood tests, and brain MRI scans before and after treatment\n* Have their ketone levels checked regularly throughout the 12-week period",[223,224],"Major Depressive Disorder (MDD)","Treatment Resistant Depression (TRD)",[226,227,228,229,230,231,232,233,234,235,236,237,238,239],"Major Depressive Disorder","MDD","TRD","TMS","Glucose Control","Ketogenic Diet","Metabolic Health","Transcranial Magnetic Stimulation","iTBS","Dietary Intervention","Metabolic Psychiatry","MRS","fMRI","Intermittent Theta-Burst Stimulation",{"date":241,"type":42},"2026-08-07",{"date":243,"type":21},"2026-08",{"date":245,"type":21},"2028-01",{"name":48,"class":49},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":50},"100629600","exploring-the-feasibility-of-cerebrospinal-fluid-csf-and-blood-plasma-liquid-biopsy-in-patients-with-metastatic-solid-tumours-and-primary-central-nervous-system-cns-tumours-a-pilot-study-100629600","NCT07476781","Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study","ECLIPSE","Inclusion Criteria:\n\n* Diagnosed with a solid tumour in one of the following scenarios:\n\n  1. Patients in Cohort A will have previously untreated or progressing leptomeningeal metastatic disease (LMD) with or without parenchymal brain metastases (BrM).\n  2. Patients in Cohort B will have previously untreated or BrM but no evidence of LMD.\n  3. Patients in Cohort C will have progressing extra-cranial metastatic disease with no LMD or BrM.\n  4. Patients in Cohort D will have primary CNS tumours (such as, but not limited to, meningioma, glioblastoma, astrocytoma, ependymoma, and other rare histologies).\n* Patient is suitable for lumbar puncture and\u002For has an Ommaya reservoir that is accessible for CSF collection.\n* Patient is eligible at any time point in their treatment course, including whether or not they have already started treatment for LMD. Considering the poor prognosis associated with LMD, rapid clinical deterioration, and the fact that available local and systemic therapies have not been shown to completely eradicate LMD, there is a high likelihood of detecting CSF biomarkers regardless of the timing of assessment. This flexible enrollment strategy is particularly important to support feasibility and recruitment in this less common and clinically challenging population. However, efforts will be made to collect CSF samples prior to treatment initiation and\u002For at the time of disease progression whenever possible.\n* Patients with active brain metastases, defined as newly diagnosed and previously untreated lesions, or lesions that were previously treated and are now progressing.\n* Patients who were previously enrolled in the study and had negative CSF biomarkers may be re-enrolled at a later time point (e.g., upon progression of CNS disease).\n\nExclusion Criteria:\n\n* Inability to understand or unwillingness to provide written informed consent (language barriers are not exclusionary; the use of a translator is permitted).\n* Patients with contraindications to lumbar puncture (e.g., infection at the LP site, uncontrolled bleeding diathesis \\> 1.5\\], severe thrombocytopenia \\[platelet count \\\u003C40,000\u002FµL\\], use of anticoagulant or antiplatelet medications cannot be safely interrupted, significant mass effect with risk of herniation, or presence of vertebral hardware)",{"count":219,"type":21},[24],"This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease involvement, including leptomeningeal disease (Cohort A), parenchymal brain metastases (Cohort B), and no evidence of CNS metastases (Cohort C).",[258,259,260,261],"Solid Tumor Malignancies","Brain Metastasases","Leptomeningeal Disease (LMD)","Central Nervous System","2026-07-29",{"date":264,"type":42},"2026-07-31",{"date":266,"type":42},"2025-12-12",{"date":268,"type":21},"2026-12",{"name":48,"class":49},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":278,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":290},"100517198","phase-2-cannabidiol-medication-intervention-trial-100517198","NCT06014424","Cannabidiol Medication Intervention Trial","Cannabidiol Medication Intervention Trial (CALM-IT)","CALM-IT","Inclusion Criteria:\n\n1. Males or females ≥55 years of age; female must be post-menopausal or must agree to comply with contraception requirements. Males should also abide by contraceptive requirements when the partner is a woman of childbearing potential. Acceptable methods of contraception include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal; progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable; intrauterine device or intrauterine hormone-releasing system; vasectomy of a female subject's male partner (with medical assessment and confirmation of vasectomy surgical success); bilateral tubal occlusion\n2. Diagnostic and Statistical Manual of Mental Disorders-5 (DSM 5) criteria for Major Neurocognitive Disorder due to possible AD. Patients with Major Neurocognitive Disorder due to multiple etiologies (AD and vascular) will be included\n3. sMMSE ≤24\n4. Presence of clinically significant agitation based on the IPA definition at both screening and baseline\n5. If treated with cognitive-enhancing medications (cholinesterase inhibitors and\u002For memantine), dosage must be stable for at least 3 months prior to study randomization\n6. Availability of a primary caregiver to accompany the participant to study visits and to participate in the study. The primary caregiver must be sufficiently proficient in English to complete the required study assessments, as per investigator judgement and should spend at least 10 hours a week with the participant\n7. Willing and able to provide informed consent and\u002For have a Substitute Decision Maker (SDM) provide informed consent on behalf of the participant\n\nExclusion Criteria:\n\n1. Change in psychotropic medications less than the duration of 5 half-lives of the medication in question prior to screening (e.g., concomitant antidepressants or atypical antipsychotics) and any changes during study participation\n2. Contraindications to CBs, e.g. allergies to cannabis and cannabis products, potential clinically important drug-drug interactions (e.g. strong CYP3A4 inducers\u002Finhibitors, anticonvulsants)\n3. Vascular disease, clinically important cerebrovascular disease or current uncontrolled cardiovascular disease (e.g. uncontrolled hypertension, ischemic heart disease, arrhythmia and severe heart failure, cardiovascular accident in the 3 months prior to Screening (V1)), as per investigator assessment\n4. Clinically significant liver disease, as reflected by serum alanine aminotransferase or aspartate aminotransferase \\> 2 x upper limit of normal (ULN), or total bilirubin \\> 1.5 x ULN; The Investigator may decide to repeat the assessment to confirm criterion prior to screen failing the participant\n5. Clinically significant impaired renal function at screening, as per investigator assessment\n6. Currently meeting DSM 5 criteria for Major Depressive Episode Presence, or current substance dependence (excluding caffeine and nicotine) or history of other major psychiatric disorders or neurological conditions (e.g. psychotic disorders, schizophrenia, stroke, epilepsy)\n7. Substance-Related Disorders (excluding caffeine and nicotine)\n8. Clinically significant delusions and\u002For hallucinations (e.g. NPI-NH delusion\u002Fhallucinations subscore ≥4 or judgement of QI)\n9. Reported use of marijuana or cannabinoid-based medications, products or supplements (botanical or synthetic) within 1 week prior to randomization\n10. Systolic blood pressure (SBP) \\\u003C 90 mmHg or \\> 150 mmHg or diastolic blood pressure (DBP) \\\u003C 50mmHg or \\> 105 mmHg at screening or baseline (prior to randomization) or a postural drop in SBP ≥ 20 mmHg or DBP ≥ 10 mmHg at screening","55 Years",{"count":280,"type":21},40,[62],"CALM-IT is a Randomized, double-blind, placebo-controlled cross-over clinical trial. Safety and efficacy of cannabidiol (CBD) capsules assessed for managing agitation in patients with AD and to identify novel biomarkers of agitation severity and treatment response.",[28],{"date":264,"type":42},{"date":286,"type":42},"2023-09-27",{"date":288,"type":21},"2026-12-29",{"name":48,"class":49},5,{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":84,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":153},"100333150","superior-capsular-reconstruction-vs-partial-repair-for-massive-rotator-cuff-tears-100333150","NCT03617562","Superior Capsular Reconstruction vs. Partial Repair for Massive Rotator Cuff Tears","Arthroscopic Partial Repair vs. Superior Capsular Reconstruction for Massive Irreparable Rotator Cuff Tears: A Pilot Randomized and Controlled Trial","SCR","Inclusion Criteria:\n\n* Symptomatic shoulder pain and\u002F or weakness (regardless of baseline range of motion\u002F psuedoparalysis)\n* Massive rotator cuff tear, identified by MRI as being greater than 4 cm in greatest diameter, and involvement of the entire supraspinatus and infraspinatus.\n* Failure of at least a 3 month trial of non-surgical treatment including physiotherapy and activity modifications\n* Irreparable tear determined intra-operatively using standard arthroscopic techniques\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Absence of subscapularis muscle insertion, or irreparable subscapularis tear\n* Advanced rotator cuff tear arthropathy (Hamada Grade 3+) or glenohumeral osteoarthritis (Samilson-Prieto grade 2+)\n* Acute tears (within 6 months)\n* Neurologic injury causing paralysis of affected shoulder \u002F arm\n* Any previous surgery to the affected shoulder\n* Limited life expectancy due to significant medical co-morbidity or medical contraindication to surgery (ASA Grade IV or higher)\n* Anticipated problems with ability to maintain follow-up in the judgement of the investigators (ie. patients with no fixed address, etc.)\n* Are there any non-orthopedic comorbidities that put the patient at significant risk?",{"count":300,"type":21},70,[24],"Little evidence exists to guide treatment in patients with massive irreparable rotator cuff tears (MRCTS). Arthroscopic partial rotator cuff repair (PRCR) has the longest record of use. The new technique of superior capsular reconstruction (SCR) has more recently been described. Despite high enthusiasm for this technique, its effectiveness, cost and safety profile have not been established.\n\nThe long-term goal of this study is to perform a multicenter randomized control trial to evaluate the effectiveness of SCR compared to PRCR in patients with MRCTS. The current study is a pilot required to support the development of an expanded formal clinical trial.",[304],"Rotator Cuff Tear",[306,307],"Massive Rotator Cuff Tear","Shoulder Injuries",{"date":309,"type":42},"2026-07-30",{"date":311,"type":42},"2018-07-18",{"date":313,"type":21},"2028-07",{"name":48,"class":49},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":18,"minAge":278,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":330,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":153},"100629650","phase-2-levetiracetam-for-persons-at-risk-for-alzheimers-disease-100629650","NCT07477431","Levetiracetam for Persons at Risk for Alzheimer's Disease","A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease","ALEVIATE-2","Inclusion Criteria:\n\n* Willing to undergo all study procedures and has signed the informed consent form\n* Within normal limits on the Montreal Cognitive Assessment (MoCA) at Screening\n* Age 55-85\n* Female participants must be post-menopausal (amenorrheic for at least 12 consecutive months without other known or suspected cause) or surgically sterile (bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy)\n* Sufficiently fluent in English to undergo cognitive testing, per investigator judgment\n* Increased risk of Alzheimer's disease, as indicated by one or more of the following:\n\n  1. Participant has subjective cognitive complaints AND a family history of Alzheimer's disease (or of dementia suggestive of possible or probable Alzheimer's disease) in a first-degree relative; and\u002For\n  2. Participant is known to be amyloid or tau positive; and\u002For\n  3. Participant is known to be an APOE e4\u002Fe4 homozygote\n* Hippocampal hyperactivation, defined as activation \\>1.5 MAD above the median, during the pattern separation task (PST) on BOLD fMRI.\n\nExclusion Criteria:\n\n* History of hypersensitivity to levetiracetam or any other ingredients in the study drug or placebo.\n* Significant neurological disease, including but not limited to:\n\n  1. Any type of cognitive impairment\n  2. History of transient ischemic attacks within 12 months of Screening\n  3. History of seizures within 12 months of Screening\n  4. Epilepsy\n  5. Parkinson's disease\n  6. Stroke (aside from subcortical lacunar infarcts)\n  7. Multiple sclerosis\n  8. Huntington's disease\n  9. Normal pressure hydrocephalus\n  10. Brain tumour (aside from benign tumours without mass effect, which are to be judged on a case-by-case basis)\n  11. Subdural hematoma\n  12. History of traumatic brain injury with persistent neurological deficits\n  13. Known structural brain abnormalities\n* Significant or unstable psychiatric disease, including but not limited to:\n\n  1. Schizophrenia\n  2. Bipolar disorder\n  3. Major depression which is not controlled in the opinion of the investigator\n  4. Score ≥10 on the Geriatric Depression Scale (GDS) at Screening\n  5. Presence of active suicidal ideation within the last 3 months as indicated by \"yes\" response to Question 4 or 5 on the Suicidal Ideation portion of the C-SSRS at Screening\n  6. Answered \"yes\" to any of the suicide-related behaviours within the last 3 months on the Suicidal Behavior portion of the C-SSRS\n  7. Hospitalized or treated for suicidal behavior within 5 years of Screening\n  8. Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol in the opinion of the investigator\n* Known or suspected history of drug or alcohol abuse or dependence within 2 years before Screening).\n* Significant or unstable systemic illness or medical condition that would in the investigator's judgment make the participant unsuitable for inclusion in the study, including but not limited to:\n\n  1. History of malignancy within 3 years of screening (except of basal or squamous cell carcinoma of the skin)\n  2. Moderate-severe chronic kidney disease, chronic obstructive pulmonary disease, or congestive heart failure\n* Any of the following findings on a current (completed during screening) or previous brain MRI\u002FCT scan:\n\n  1. Severe white matter disease (Fazekas score66 = 3)\n  2. Stroke involving a major vascular territory\n  3. Subcortical lacunar infarcts \\>1.5cm in diameter\n  4. Encephalomalacia\n  5. Vascular malformations that are at high risk of hemorrhage\n  6. Infective lesions\n  7. Space-occupying lesions\n  8. Any other abnormality that would in the opinion of the investigator make the participant unsuitable for participation in the study\n* Any contraindications to MRI or MEG (e.g., pacemaker, ferromagnetic metal implants, claustrophobia).\n* Treatment with the following medications at time of screening or while in the study:\n\n  1. Anticonvulsant medications (unless taken for a different indication than seizures)\n  2. Methotrexate\n* eGFR \\\u003C50ml\u002Fmin\u002F1.73m2 on screening bloodwork.\n* QTc interval \\>470 msec (males) or \\>480 msec (females) on screening ECG.\n* Clinically significant abnormal results on screening bloodwork that would in the opinion of the investigator make the participant unsuitable for inclusion in the study.","85 Years",{"count":280,"type":21},[62],"The goal of this clinical trial is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce elevated brain signaling in individuals who are at an increased risk for developing Alzheimer's Disease (AD). The study is looking for people who are currently performing within normal limits on memory testing but who have one or more of the following risk factors for developing AD:\n\n1. People who feel like their memory is getting worse and who have a parent or sibling with Alzheimer's disease (dementia)\n2. People with two copies of the APOE E4 gene\n3. People who have tested positive for a biomarker of AD (e.g., blood p-tau test, brain amyloid PET scan)\n\nDuring the screening period, a functional MRI (fMRI) scan of the brain will identify those participants who have the increased brain signaling that the study is looking to treat.\n\nAll participants will receive 4 weeks of treatment with LEV and 4 weeks of treatment with placebo (a sugar pill), but it will not be known what order they will receive them in. Participants will undergo cognitive testing, genetic testing, and several brain imaging scans as part of the study.\n\nThis is a pilot study, meaning that it is being carried out for the first time in a small number of participants. If the results show that treatment with LEV appears to be more beneficial than placebo in normalizing brain signaling, a larger study may follow.\n\nThis study is only being carried out in Toronto, Canada.",[328,329],"Hippocampal Hyperactivation","Prodromal Alzheimer Disease",[331,238,332,333,334,335,336,337,338,339,28],"EEG-MEG","Pattern Separation Task","PST","Levetiracetam","Crossover Design","AD","Prodromal AD","Hippocampal hyperactivation","Subjective cognitive complaints","2026-07-28",{"date":262,"type":42},{"date":343,"type":42},"2025-10-23",{"date":345,"type":21},"2028-02",{"name":48,"class":49},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":161,"sex":18,"minAge":354,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":364,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":153},"100647385","better-access-to-and-integration-of-mental-health-and-addiction-services-through-navigation-a-mixed-methods-adaptive-pragmatic-clinical-trial-100647385","NCT07707492","Better Access to and Integration of Mental Health and Addiction Services Through Navigation: A Mixed-Methods Adaptive Pragmatic Clinical Trial","BEAM","Inclusion Criteria:\n\nIndividuals who meet the established eligibility criteria for the Family Navigation Project (FNP), specifically:\n\n* Youth ages 11 to 29 years old who are experiencing a mental health and\u002For addictions (MHA) concern OR\n* Family members or caregivers (broadly defined, including family of choice) of youth ages 11 to 29 years old who are experiencing a MHA concern.\n* No maximum age limit for participants who are the family of a youth experiencing a MHA concern, as long as the youth is within the eligible age range.\n* The youth experiencing a MHA concern OR the family member must reside within the districts of Sudbury, Greater Sudbury, or Manitoulin to be eligible for inclusion.\n* Participants must enroll in the clinical trial within the two-month period following the date of their intake with FNP Sudbury-Manitoulin.\n\nExclusion Criteria:\n\n* Individuals will be excluded if they fall outside of the eligible age range for the Family Navigation Project (i.e., younger than 11, older than 29) or if they are not experiencing a mental health and\u002For addictions concern.\n* Participants will also be excluded if the youth with MHA concerns or the family member do not reside within the designated catchment area of Sudbury, Greater Sudbury, or Manitoulin.\n* Individuals older than 29 may only be included if they are participating in this study as a family member of an eligible youth (aged 11-29) who is experiencing a MHA concern.","11 Years",{"count":356,"type":21},480,[24],"The Family Navigation Project (FNP), a youth and family mental health and addictions (MHA) navigation service that currently operates in the Greater Toronto Area (GTA), is expanding to northern Ontario by setting up a new site in the Sudbury and Manitoulin districts. This work is being done in partnership with Compass\u002FBoussole\u002FAkii-Izhinoogan, the lead child and youth mental health agency for Sudbury-Manitoulin. An innovative clinical trial will be conducted following the setup of FNP in Sudbury-Manitoulin, which will test how well the model works for the community in this area. The team will collect information about the experiences and outcomes of the youth and families who use the service. The goal is to see whether FNP leads to better outcomes for youth and families, such as getting help sooner, feeling more supported, and being able to use the healthcare system more efficiently. The trial will use a mixed methods approach, meaning it gathers both numbers (e.g., wait times and service use) and personal experiences (e.g., whether families feel supported). This will provide a rich, in-depth picture of how navigation services work in a northern community and how they impact the lives of young people and their families living there.",[360,361,362,363],"Mental Health","Addictions","Patient Navigation","Health Services",[360,361,365,366,367,368,362,363],"Navigation","Youth","Family","Northern Ontario","2026-07-15",{"date":371,"type":42},"2026-07-16",{"date":373,"type":21},"2026-10",{"date":375,"type":21},"2029-10",{"name":48,"class":49},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":323,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":392,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":50},"100647237","safety-and-feasibility-of-fus-next-generation-dome-helmet-ngdh-to-perform-neuromodulation-in-patients-with-treatment-refractory-obsessive-compulsive-disorder-ocd-100647237","NCT07704632","Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD)","Assessment of Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD)","Inclusion Criteria:\n\n1. Must be deemed to have the capacity to provide informed consent.\n2. Age 18 to 85 years.\n3. Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria.\n4. Yale-Brown Obsessive Compulsive Scale total score greater than 22.\n5. If taking psychiatric medications, must be on a stable regimen for at least 30 days before enrollment. Psychiatric medications will be continued throughout the study.\n6. Previous trial of at least two first-line antidepressant agents at an adequate dose and duration, as assessed by two psychiatrists.\n7. Previous trial of cognitive behavioural therapy or psychotherapy for OCD for at least 6 weeks.\n\nExclusion Criteria:\n\n1. Pregnant or intending to become pregnant during the study.\n2. Substance use disorder, other than cannabis or nicotine use disorder, of moderate severity or greater, or where the substance is the primary substance of concern, according to DSM-5 criteria.\n3. Known active seizure disorder or significant head injury with an imaging-confirmed lesion.\n4. Unstable medical illness.\n5. Not eligible for 3-Tesla MRI, such as due to an MRI-incompatible pacemaker or other implanted device.\n6. Unable to reliably attend the required screening, treatment, and follow-up visits.\n7. Severe claustrophobia that would prevent MRI scanning.\n8. History of a bleeding disorder or coagulopathy.\n9. Anticoagulant therapy or use of medications known to increase the risk of hemorrhage within the required washout period before treatment, including:\n\n   * Antiplatelet agents or vitamin K antagonist anticoagulants within 7 days of treatment\n   * Non-vitamin K oral anticoagulants within 72 hours of treatment\n   * Heparin-derived compounds within 48 hours of treatment",{"count":385,"type":21},20,[24],"This study evaluates the safety, feasibility, and preliminary efficacy of focused ultrasound (FUS) neuromodulation delivered using the Next Generation Dome Helmet (NGDH) in participants with treatment-refractory obsessive-compulsive disorder (OCD). Participants will undergo two study sessions, four weeks apart, involving active FUS neuromodulation targeting nodes of the cortico-striato-thalamo-cortical (CTSC) circuit. Outcomes include adverse events, changes in OCD symptom severity, and quality of life.",[389,390,391],"OCD","Obsessive-Compulsive Disorder (OCD)","Obsessive-Compulsive Disorder",[393,394,395],"Focused ultrasound (FUS)","MRgFUS","FUS Neuromodulation","2026-07-10",{"date":369,"type":42},{"date":399,"type":42},"2025-09-23",{"date":401,"type":21},"2027-09",{"name":48,"class":49},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":412,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":426,"locationsCount":50},"100647060","safety-and-feasibility-of-next-generation-dome-helmet-ngdh-for-focused-ultrasound-neuromodulation-in-substance-use-disorder-sud-100647060","NCT07684976","Safety and Feasibility of Next-Generation Dome Helmet (NGDH) for Focused Ultrasound Neuromodulation in Substance Use Disorder (SUD)","Assessment of Safety and Feasibility of Focused Ultrasound (FUS) Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Substance Use Disorder (SUD)","Inclusion Criteria:\n\n1. Must be deemed to have capacity to provide informed consent (determined by the investigator)\n2. Age between 18 to 70 (inclusive)\n3. Diagnosis of SUD (cannabis, alcohol, ketamine, stimulant, opioid or nicotine\u002Ftobacco use disorder) in the moderate to severe range according to the DSM-5\n4. Previous ≥2 pharmacotherapy trials for the diagnosed SUD according to guideline-concordant, evidence-based care\n5. On a stable regimen of their psychiatric medications for 30 days before enrolment.\n\nExclusion Criteria:\n\n1. Pregnant or intending to be pregnant during the study\n2. Known active seizure disorder, significant head injury with an imaging verified lesion\n3. Medical illness that is deemed to be unstable or may confound the effects of the intervention\n4. Not eligible for 3-Tesla MRI (i.e. MRI-incompatible pacemaker)\n5. Unable to reliably attend the required screening, treatment, and follow up appointments.\n6. Severe claustrophobia, identified by the subject to be a limiting factor preventing MRI.\n7. Scores 18 or below on Montreal Cognitive Assessment (MoCA)\n8. Weighs 250 lbs or more.","70 Years",{"count":385,"type":21},[24],"The goal of this clinical trial is to evaluate the safety, feasibility, and preliminary clinical benefit of focused ultrasound (FUS) neuromodulation using the FUS Next Generation Dome Helmet (NGDH) in adults with treatment-resistant moderate-to-severe substance use disorder (SUD).\n\nThe main questions it aims to answer are:\n\nCan FUS neuromodulation be safely delivered to the nucleus accumbens (NAc) and\u002For anterior insula (aI)? Does FUS neuromodulation result in reduced substance use severity, as measured by Timeline Followback (TLFB), by 4 weeks post-treatment?\n\nParticipants will:\n\nComplete baseline clinical assessments, questionnaires, imaging, and safety assessments.\n\nUndergo two MRI-guided FUS neuromodulation sessions approximately 4 weeks apart.\n\nAttend follow-up visits for safety monitoring, symptom assessments, quality-of-life measures, and additional imaging where applicable.",[415],"Substance Use Disorder (SUD)",[417,418,419],"Neuromodulation","Focused Ultrasound (FUS)","treatment-refractory substance use disorder","2026-07-02",{"date":422,"type":42},"2026-07-06",{"date":424,"type":21},"2026-07",{"date":313,"type":21},{"name":48,"class":49},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":440,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":50},"100646319","assessment-of-safety-and-feasibility-of-fus-next-generation-dome-helmet-ngdh-to-perform-neuromodulation-in-patients-with-disorders-of-consciousness-100646319","NCT07694258","Assessment of Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Disorders of Consciousness","Inclusion Criteria:\n\n1. Diagnosis of severe traumatic brain injury, hypoxic-ischemic brain injury, or other acute brain injury.\n2. Glasgow coma scale below 13 when off sedation, or on minimal sedation.\n3. Absence of another better explanation for the depressed level of consciousness (e.g,, metabolic abnormality, seizures)\n4. Intracranial pressure (ICP) is within a normal range (\\\u003C 20 cm H2O), or, a neurosurgeon associated with the study and\u002For the treating physician agree that ICP is likely \\\u003C 20 cm H2O based on clinical and neuroimaging information (acknowledging the limitations of non-invasive assessment of ICP53).\n5. The treating physician and\u002For neurosurgeon associated with the study evaluate it to be safe for the patient to be transported to the MRI scanner for a \\~45 minute scan.\n\nExclusion Criteria:\n\n1. Active seizure activity or post-anoxic myoclonus at the time of proposed treatment\n2. Taking full anti-coagulation medication (does not include deep-vein-thrombosis chemoprophylaxis)\n3. Skull anatomy incompatible with safe FUS delivery (as determined by CT)\n4. Medical instability that would preclude safe transport or prolonged supine positioning\n5. Presence of any MRI-incompatible implants or devices",{"count":434,"type":21},10,[24],"The main questions this study aims to answer are:\n\nCan low-intensity FUS neuromodulation be safely and feasibly administered to the bilateral central thalamus in patients with disorders of consciousness (DoC)? Does FUS neuromodulation result in short-term improvements in arousal or behavioral responsiveness? Does FUS neuromodulation produce measurable changes in neural activity on EEG and\u002For fMRI?\n\nParticipants will:\n\nReceive two sessions of low-intensity FUS neuromodulation, spaced four weeks apart, plus or minus one week.\n\nUndergo pre- and post-treatment assessments, including planning CT, MRI\u002FfMRI, EEG, and standardized clinical scales such as the Coma Recovery Scale-Revised (CRS-R) and Glasgow Coma Scale (GCS).\n\nBe continuously monitored for safety during and after each FUS treatment. Complete follow-up imaging and clinical assessments approximately 2 weeks after each FUS session, 12 weeks after the second treatment, and at 12 months post-injury when clinically feasible.",[438,439],"Disorders of Consciousness Due to Severe Brain Injury","Disorders of Consciousness",[441,442,443],"focused ultrasound","FUS","neuromodulation",{"date":445,"type":42},"2026-07-09",{"date":447,"type":42},"2025-09-10",{"date":449,"type":21},"2028-09",{"name":48,"class":49},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":460,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":470,"locationsCount":50},"100616667","evaluation-of-intercostal-neuralgia-in-patients-with-chest-tube-insertion-after-traumatic-rib-fracture-100616667","NCT07308587","Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture","Prospective Evaluation of Intercostal Neuralgia Incidence, Risk Factors, and Outcomes in Patients With Chest Tube Insertion After Traumatic Rib Fractures","Inclusion Criteria:\n\n* Adults (≥18 years) with traumatic rib fractures requiring chest tube insertion\n* Chest tube or pigtail insertion performed during their initial hospitalization for trauma\n\nExclusion Criteria:\n\n* Patients with spinal cord injury\n* Inability to complete follow-up assessments (e.g., language barriers, lack of telephone access)\n\nExclusion Criteria:\n\n* Patients with traumatic brain injury\n* Patients with spinal cord injury\n* Inability to complete follow-up assessments (e.g., language barriers, lack of telephone access)",{"count":459,"type":21},100,"OBSERVATIONAL","Traumatic rib fractures are common injuries following blunt chest trauma, often requiring chest tube insertion to manage complications such as pneumothorax or haemothorax. However, chest tube placement can lead to intercostal nerve injury, resulting in intercostal neuralgia-a debilitating condition characterized by chronic, neuropathic pain along the intercostal nerves. Despite its clinical significance, the incidence, risk factors, and long-term outcomes of intercostal neuralgia in this patient population remain poorly understood.\n\nChronic pain following thoracic trauma, including intercostal neuralgia, has been shown to significantly impair quality of life and functional outcomes, leading to prolonged disability and increased healthcare utilization. Current literature highlights the need for better understanding and management of this condition, particularly in patients undergoing invasive procedures such as chest tube insertion. This study aims to prospectively evaluate the development of intercostal neuralgia in patients with chest tube insertion following traumatic rib fractures.",[463],"Intercostal Nerve Injury","2026-05-13",{"date":466,"type":42},"2026-05-15",{"date":468,"type":42},"2026-01-19",{"date":151,"type":21},{"name":48,"class":49},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":479,"minAge":59,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":50},"100529693","pilot-study-of-dose-escalation-in-prostate-radiotherapy-using-the-mr-linac-destination-mrl-100529693","NCT06177093","Pilot Study of Dose Escalation in Prostate Radiotherapy Using the MR-Linac (DESTINATION-MRL)","A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL","DESTINATION-MR","Inclusion Criteria:\n\n* Men aged ≥18 years\n* Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy\n* Gleason score 3+3, 3+4 or 4+3 (Grade groups 1, 2 or 3)\n* MRI stage T2 or less (as staged by AJCC TNM 2018)\n* MRI-visible tumour(s) of PIRADS v2 grade 3 or higher on T2 and diffusion-weighted imaging and\u002For dynamic contrast-enhanced imaging (multiparametric MRI or mpMRI) with concordant pathology\n* Tumour nodule visible on MRI occupying \\\u003C50% of prostate on any axial slice and \\\u003C50% prostate volume\n* PSA \\\u003C20 ng\u002Fml prior to starting ADT (if applicable)\n* Short course (\\\u003C 6 months) concurrent androgen deprivation therapy (antiandrogens or LHRH analogues) allowed though not mandated as per the discretion of the treating physician.\n* WHO Performance status 0-2\n* Ability of the participant understand and the willingness to sign a written informed consent form.\n* Ability\u002Fwillingness to comply with the patient reported outcome questionnaires schedule throughout the study.\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)\n* IPSS 19 or higher\n* High grade disease (GG3) occult to MRI-defined lesion\n* Post-void residual \\>100 mls, where known\n* Prostate volume \\>90cc\n* Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up\n* Unilateral or bilateral total hip replacement, or other pelvic metalwork which causes artefact on diffusion-weighted imaging\n* Previous pelvic radiotherapy\n* Patients needing \\>6 months of ADT due to disease parameters as per the discretion of the treating physician\n* Previous invasive malignancy within the last 2 years excluding basal or squamous cell carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming cystoscopic follow up now negative) or small renal masses on surveillance.","MALE",{"count":385,"type":21},[24],"This study is a single centre feasibility trial. The trial will recruit men with intermediate risk localised prostate cancer who will all receive targeted dose (escalated\u002Fde-escalated dose directed by MRI) 5 fraction SBRT to the prostate.\n\nTrial Objectives are:\n\n1. Primary To develop a 5 fraction de-escalated dose SBRT protocol capable of reducing side effects\n2. Secondary\n\n   * To assess levels of acute GU and GI toxicity (CTCAE)\n   * To assess levels of late GU and GI toxicity (CTCAE)\n   * To assess late sexual quality of life (expanded EPIC, IIEF-5)\n   * To assess biochemical relapse-free survival at 2",[484],"Prostate Cancer",[486],"Newly diagnosed intermediate risk localized prostate cancer",{"date":466,"type":42},{"date":489,"type":42},"2023-12-11",{"date":491,"type":21},"2027-12-01",{"name":48,"class":49},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":4},"100626373","goal-directed-therapy-to-reduce-kidney-and-cardiovascular-risk-in-diabetic-kidney-disease-gold-standard-100626373","NCT07434791","Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)","GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease","GOLD-STANDARD","Inclusion Criteria\n\n1. Age ≥ 18 years\n2. T2DM\n3. CKD (eGFR ≥ 25-60 OR UACR ≥ 30 mg\u002Fg)\n4. High Cardiovascular (CV) Risk: Defined as a history of prior myocardial infarction (MI), stroke, or peripheral artery disease (PAD), or the presence of cardiovascular risk factors, (specifically age 40 years or older and at least one of the following: cholesterol above target (LDL≥1.8 mmol\u002FL OR on cholesterol lowering medication), hypertension (≥130\u002F80 mmHg or on BPLMs), or atrial fibrillation.)\n5. Open to start new medications\n\nExclusion Criteria:\n\n1. Type 1 diabetes\n2. HbA1c ≥10% on screening labs\n3. Serum potassium ≥ 5.2 mmol\u002FL on screening labs\n4. Baseline Blood Pressure (BP) \\\u003C 100\u002F60 mmHg at screening\n5. Treated with new or intensified immunosuppression therapy for new (or relapse\u002Fflare of pre-existing) kidney disease within the last 60 days\n6. Kidney Transplant\n7. Use of ≥3 medication classes: Participants already prescribed three or more of the following classes of medications: RASi, SGLT2i, nsMRA or GLP1RA\n8. Intolerance or allergy to any of RASi, SGLT2i, nsMRA or GLP1RA\n9. Known Heart Failure with Reduced Ejection Fraction (HFrEF)\n10. Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception",{"count":459,"type":21},[24],"GOLD-STANDARD is a pragmatic, open-label pilot randomized controlled trial evaluating the feasibility and safety of early goal-directed Cardio-Kidney-Metabolic (CKM) care compared with usual care in patients with diabetic kidney disease. Participants will be randomized 1:1 and managed by nephrologists.\n\nThe intervention includes structured kidney and cardiovascular risk assessment, early shared decision-making regarding guideline-directed medical therapies, and close monitoring for adverse effects. The usual care group will receive standard clinical management at the discretion of the treating clinician. The study will be conducted in Ontario using existing health care infrastructure.",[505],"Diabetic Kidney Disease (DKD)",[507,508,509,510],"diabetes","diabetic kidney disease","cardiovascular risk","Cardio-Kidney-Metabolic (CKM) care","2026-05-01",{"date":513,"type":42},"2026-05-07",{"date":515,"type":21},"2026-06",{"date":517,"type":21},"2029-03",{"name":48,"class":49},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":22,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":4},"100606099","this-study-will-use-real-time-pressure-mapping-technology-to-determine-which-positioning-strategies-and-devices-exert-the-least-amount-of-pressure-on-peri-operative-burn-patients-100606099","NCT07171138","This Study Will Use Real-time Pressure Mapping Technology to Determine Which Positioning Strategies and Devices Exert the Least Amount of Pressure on Peri-operative Burn Patients","Pressure Injury Risk Related to Positioning and Positioning Devices in Burn Patients","Inclusion Criteria:\n\n* adult patients (18 years of age or greater)\n* burns of any size\n* pre and post-operative patients\n\nExclusion Criteria:\n\n* pediatric burn patients\n* patients with pre-existing (pre-admission) pressure injuries\n* patients unable to provide informed consent or decline consent\n* patients with large burns that are not expected to survive past 72 hours",{"count":86,"type":21},[24],"Burn patients are especially vulnerable to developing hospital-acquired pressure sores. The goal of this study is to determine which positions and positioning devices exert the least amount of pressure on problem areas such as the heels, the tailbone, the elbow and the back of the head.\n\nWith the use of a pressure mapping device, it will allow the investigators to:\n\n1. Identify patients at the highest risk of developing pressure injuries related to positioning\u002Fdevices.\n2. Use the findings to create positioning\u002Fdevice guidelines\n\nBy optimizing positioning strategies, the investigators aim to enhance patient comfort, prevent complications, and ultimately improve the overall quality of care for burn patients.",[530],"Hospital Acquired Pressure Injury",{"date":532,"type":42},"2026-05-05",{"date":534,"type":21},"2026-05",{"date":536,"type":21},"2027-03",{"name":48,"class":49},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":161,"sex":18,"minAge":545,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":553,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":4},"100583240","neuromodulation-and-fmri-in-neurodegenerative-diseases-study-100583240","NCT06873750","Neuromodulation and fMRI in Neurodegenerative Diseases Study","A Pilot Study in Defining the Potential of Transcranial Alternating Current Neuromodulation for Stabilizing Memory and Improving Functional Connectivity in Neurodegeneration","Inclusion Criteria:\n\n1. Be at least 25 years of age;\n2. Have no contraindications to MRI\n3. Have received 8 or more years of formal education\n4. Be fluent in English\n5. Cohort a. must be followed at Sunnybrook Health Sciences Center\n\nCohort a:\n\n* Have been diagnosed with a suspected neurodegenerative disorder or traumatic brain injury (TBI) with memory deficits impacting functional status\n* In case of TBI, cognitive impairment has persisted at least three months post-injury\n* Received score of 16 or lower on the Mini Mental State Examination (MMSE)\n\nCohort b:\n\n* Have no prior diagnosis of a neurodegenerative disorder or post-traumatic brain injury cognitive deficits\n* Be experiencing healthy aging and be age and sex matched to Cohort a.\n\nExclusion Criteria:\n\n1. Have any contraindications to MRI\n2. Be pregnancy\n3. Have any major comorbid medical conditions (as determined by investigators - e.g., comorbid neurological diseases, uncontrolled hypertension or diabetes, malignancy) or major comorbid psychiatric conditions (as determined by investigators - e.g., schizophrenia or bipolar disorder)","25 Years",{"count":547,"type":21},30,[24],"In addition to neuronal loss, dysfunction in brain network connectivity has been identified as a correlate of cognitive deficits in neurodegenerative and post-traumatic brain injury states. Transcranial alternating current stimulation (tACS) has been suggested as a promising, non-invasive, method of normalizing network connectivity and hence improving cognition, notably memory. This study will examine the efficacy of tACS at improving working memory performance in patients with neurodegeneration and its correlation to changes in network connectivity, based on functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) imaging data.",[30,551,552],"Traumatic Brain Injury","Neurodegeneration",[554,417,555,556],"Transcranial Alternating Current Stimulation","Functional Magnetic Resonance Imaging","Cognitive Assessment","2026-04-27",{"date":511,"type":42},{"date":560,"type":21},"2026-06-01",{"date":562,"type":21},"2028-12-01",{"name":48,"class":49},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":578,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":590},"100472091","the-canadian-cabg-or-pci-in-patients-with-ischemic-cardiomyopathy-trial-stich3c-100472091","NCT05427370","The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)","The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial","Inclusion Criteria:\n\n1. Age \\>18 years;\n2. LVEF ≤40% quantified by either echocardiography, SPECT ventriculography, or magnetic resonance within 2 months of randomization;\n3. Prognostically important multivessel CAD (triple vessel CAD or double vessel disease including the left anterior descending (LAD) or LM). Significant coronary stenosis is defined as ≥ 70% based on coronary angiography, and\u002For fractional flow reserve (FFR) ≤0.80 or instantaneous wave-free ratio (iFR) ≤0.89. For LM disease, significant coronary stenosis is defined as \\>50% based on coronary angiography, intravascular ultrasound (IVUS) minimal luminal area (MLA) ≤6.0 mm2 (\\\u003C4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements;\n4. The institutional Heart Team agrees that guideline-directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Decompensated HF requiring inotropic\u002Fadrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump\u002Fventricular assist device therapy less than 48 hours prior to randomization;\n2. Recent (\\\u003C4 weeks) ST-elevation MI;\n3. Concomitant severe valvular disease or other condition such as left ventricular aneurysm requiring surgical repair or replacement;\n4. Planned major concomitant surgical procedures (LAAO and AF ablation surgical procedures permitted);\n5. Prior PCI within the past 12 months (to reduce restenosis events from prior PCIs contributing to the primary outcome);\n6. Prior cardiac surgery;\n7. Prohibitive bleeding risk mandating avoidance of dual antiplatelet therapy;\n8. Circumstances likely to lead to poor treatment adherence;\n9. Severe end-organ dysfunction (such as dialysis, liver failure, respiratory failure, cancer) that reduces life expectancy to less than 5 years;\n10. Current pregnancy;\n11. Patient not amenable to both CABG or PCI according to the Heart Team;\n12. Takotsubo\u002FTakotsubo Cardiomyopathy\u002FBroken Heart Syndrome.",{"count":572,"type":21},754,[24],"The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel\u002Fleft main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF).\n\nThe primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel\u002FLM CAD and ischemic left ventricular dysfunction (iLVSD).\n\nEligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization.\n\nThe secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.",[576,577],"Coronary Artery Disease","Heart Failure Systolic",[579,580,581,582],"Left ventricular dysfunction","CABG","PCI","MACCE",{"date":584,"type":42},"2026-04-28",{"date":586,"type":42},"2023-06-22",{"date":588,"type":21},"2029-12",{"name":48,"class":49},43,{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":22,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":604,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":50},"100441049","assessment-of-quality-of-life-and-outcomes-in-patients-with-primary-renal-cell-carcinoma-treated-with-sbrt-100441049","NCT05023265","Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT","Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II Study","AQuOS-II","Inclusion Criteria:\n\n* Patients ≥18 years old\n* Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)\n* Primary lesion \\>3 cm, or recurrent lesion following local ablative therapy\n* Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting\n* ECOG 0-2\n* Written informed consent\n* Participants must be able to understand the English-language or with the aid of a translator\n\nExclusion Criteria:\n\n* Primary Lesion \\>20cm\n* Evidence of distant metastatic disease\n* Previous abdominal RT in vicinity of kidney preventing definitive SBRT\n* History of major radiosensitivity syndrome\n* Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer)\n* Currently pregnant or lactating",{"count":300,"type":21},[24],"This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).",[603],"Renal Cell Carcinoma",{"date":584,"type":42},{"date":606,"type":42},"2022-02-08",{"date":608,"type":21},"2026-10-01",{"name":48,"class":49},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":4,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":18,"minAge":545,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":22,"phases":618,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":153},"100582471","using-cannabis-to-treat-restless-legs-syndrome-100582471","NCT06863740","Using Cannabis to Treat Restless Legs Syndrome","Using Cannabis to Treat Restless Legs Syndrome: A Randomized Placebo Controlled Pilot Safety and Feasibility Trial","Inclusion Criteria:\n\n* ≥25 years of age\n* diagnosis of RLS based on the International RLS Study Group criteria\n* refractory RLS symptoms despite use of dopaminergic and\u002For alpha-2-delta ligand therapy\n* onset of RLS at least 6 months before screening\n\nExclusion Criteria:\n\n* sleep disordered breathing, or sleep disordered breathing that is not adequately controlled on therapy (apnea-hypopnea index of \\>15)\n* cannabis use within 4 weeks of study enrollment\n* known allergy to cannabis, cannabinoids or palm\u002Fcoconut oil\n* Currently pregnant or breast-feeding (a negative urine pregnancy test must be obtained for women of childbearing potential during pretreatment evaluation)\n* Active substance abuse\n* Ischemic heart disease with unstable angina or recent acute coronary syndrome in the last 3 months, uncontrolled arrhythmias, poorly controlled hypertension\n* Serious liver disease\n* History of schizophrenia or any other psychotic disorder",{"count":547,"type":21},[24],"Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.",[621],"Restless Leg Syndrome (RLS)","2026-04-22",{"date":584,"type":42},{"date":625,"type":42},"2025-07-25",{"date":627,"type":21},"2027-05",{"name":48,"class":49},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":22,"phases":639,"briefSummary":640,"conditions":641,"keywords":644,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":655},"100502942","clinical-evaluation-of-antiseptic-skin-preparation-in-revision-total-joint-arthroplasty-of-the-hip-and-knee-100502942","NCT05828810","CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee","CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee - A Vanguard Randomized Controlled Registry Trial (CLEAN Joint Trial)","CLEANJoint","Inclusion Criteria:\n\n1. Aged 18 years or older\n2. Scheduled to undergo aseptic revision total hip arthroplasty or total knee arthroplasty with exchange of at least one prosthetic component\n\nExclusion Criteria:\n\n1. Revision for prosthetic joint infection or wound complication\n2. Known history of previous prosthetic joint infection in the operative joint\n3. Any degree of clinical concern for prosthetic joint infection\n4. History of allergy to iodine, chlorhexidine, or alcohol",{"count":638,"type":21},400,[24],"The goal of this clinical trial is to compare two types of skin preparation solutions (chlorhexidine gluconate-alcohol solution and povidone-iodine solution) that help eliminate harmful bacteria on the skin at the time of surgery for patients having revision arthroplasty surgery of the hip or knee.\n\nThe main outcome of interest for the definitive study is the need for re-operation for a wound complication or an infection of the prosthetic joint within one year after surgery.\n\nFor the pilot trial, our main interest is to determine feasibility of a definitive trial. Feasibility outcomes will include: ability to recruit patients, ability to randomize patients, ability to collect complete data, estimate the event rate of our primary outcome, ability to carry out data linkages and determine the accuracy of collected data.\n\nParticipants will be contacted at two time points after surgery to complete a 5-minute survey: after 30 days, and after 1 year.",[642,643],"Revision Total Hip Arthroplasty (RTHA)","Revision Total Knee Arthroplasty",[645,646,647],"prosthetic joint infection","registry-based RCT","PJI",{"date":649,"type":42},"2026-04-24",{"date":651,"type":42},"2023-07-25",{"date":653,"type":21},"2026-11",{"name":48,"class":49},3,""]